Literature DB >> 27853939

Wharton's Jelly Mesenchymal Stromal Cells as a Feeder Layer for the Ex Vivo Expansion of Hematopoietic Stem and Progenitor Cells: a Review.

Melania Lo Iacono1,2, Rita Anzalone2,3, Giampiero La Rocca4,5, Elena Baiamonte1, Aurelio Maggio1, Santina Acuto1.   

Abstract

In recent years, umbilical cord blood (UCB) has been widely used as an alternative source to bone marrow (BM) for transplantation of hematopoietic stem and progenitor cells (HSPCs) in a variety of hematological and non-hematological disorders. Nevertheless, the insufficient number of UCB-HSPCs for graft represents a major challenge. HSPCs ex vivo expansion prior to transplantation is a valid strategy to overcome this limit. Several attempts to optimize the expansion conditions have been reported, including the use of mesenchymal stromal cells (MSCs) as feeder layer. Wharton's Jelly (WJ), the main component of umbilical cord (UC) matrix, is especially rich in MSCs, which are considered ideal candidates for feeder layer in co-culture systems. In fact, they can be easily harvested and grow robustly in culture, producing a confluent monolayer in a short time. Similarly to bone marrow-mesenchymal stromal cells (BM-MSCs), WJ-derived MSCs (WJ-MSCs) have been used to support hematopoiesis in vitro and in vivo. Here, we review the rationale for using MSCs, particularly WJ-MSCs, as a feeder layer for UCB-HSPCs ex vivo expansion. In addition, we report the main findings attesting the use of these MSCs as a support in hematopoiesis.

Entities:  

Keywords:  Bone marrow transplantation; Ex vivo expansion; Feeder layer; Hematopoietic and progenitor stem cells; Umbilical cord blood transplantation; Wharton’s jelly mesenchymal stromal cells

Mesh:

Year:  2017        PMID: 27853939     DOI: 10.1007/s12015-016-9702-4

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  131 in total

1.  3D co-culture of hematopoietic stem and progenitor cells and mesenchymal stem cells in collagen scaffolds as a model of the hematopoietic niche.

Authors:  Isabelle Leisten; Rafael Kramann; Mónica S Ventura Ferreira; Manfred Bovi; Sabine Neuss; Patrick Ziegler; Wolfgang Wagner; Ruth Knüchel; Rebekka K Schneider
Journal:  Biomaterials       Date:  2011-12-01       Impact factor: 12.479

Review 2.  Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.

Authors:  Rita Anzalone; Melania Lo Iacono; Tiziana Loria; Antonino Di Stefano; Pantaleo Giannuzzi; Felicia Farina; Giampiero La Rocca
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

Review 3.  Bone-marrow haematopoietic-stem-cell niches.

Authors:  Anne Wilson; Andreas Trumpp
Journal:  Nat Rev Immunol       Date:  2006-02       Impact factor: 53.106

4.  Primary cells as feeder cells for coculture expansion of human hematopoietic stem cells from umbilical cord blood--a comparative study.

Authors:  A S Magin; N R Körfer; H Partenheimer; C Lange; A Zander; T Noll
Journal:  Stem Cells Dev       Date:  2009 Jan-Feb       Impact factor: 3.272

Review 5.  Expansion and homing of umbilical cord blood hematopoietic stem and progenitor cells for clinical transplantation.

Authors:  Sudipto Bari; Kevin Kwee Hong Seah; Zhiyong Poon; Alice Man Sze Cheung; Xiubo Fan; Shin-Yeu Ong; Shang Li; Liang Piu Koh; William Ying Khee Hwang
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-30       Impact factor: 5.742

Review 6.  Mesenchymal stem cells derived from Wharton's Jelly of the umbilical cord: biological properties and emerging clinical applications.

Authors:  Aristea K Batsali; Maria-Christina Kastrinaki; Helen A Papadaki; Charalampos Pontikoglou
Journal:  Curr Stem Cell Res Ther       Date:  2013-03       Impact factor: 3.828

7.  Expansion of LTC-ICs and maintenance of p21 and BCL-2 expression in cord blood CD34(+)/CD38(-) early progenitors cultured over human MSCs as a feeder layer.

Authors:  Suzanne Kadereit; Linda S Deeds; Stephen E Haynesworth; Omer N Koc; Margaret M Kozik; Emese Szekely; Kathleen Daum-Woods; Glenn W Goetchius; Pingfu Fu; Lisbeth A Welniak; William J Murphy; Mary J Laughlin
Journal:  Stem Cells       Date:  2002       Impact factor: 6.277

8.  Human umbilical cord Wharton's jelly stem cells and its conditioned medium support hematopoietic stem cell expansion ex vivo.

Authors:  C Y Fong; K Gauthaman; S Cheyyatraivendran; H D Lin; A Biswas; A Bongso
Journal:  J Cell Biochem       Date:  2012-02       Impact factor: 4.429

9.  The comparison of interleukin 6-associated immunosuppressive effects of human ESCs, fetal-type MSCs, and adult-type MSCs.

Authors:  Chin-Kan Chan; Kang-Hsi Wu; Yun-Shen Lee; Shiaw-Min Hwang; Maw-Sheng Lee; Shuen-Kuei Liao; En-Hui Cheng; Lai-Chu See; Chi-Neu Tsai; Ming-Ling Kuo; Jing-Long Huang
Journal:  Transplantation       Date:  2012-07-27       Impact factor: 4.939

Review 10.  Umbilical cord blood transplantation: basic biology and clinical challenges to immune reconstitution.

Authors:  Julia A Brown; Vassiliki A Boussiotis
Journal:  Clin Immunol       Date:  2008-04-18       Impact factor: 3.969

View more
  9 in total

1.  Decellularized Wharton jelly matrix: a biomimetic scaffold for ex vivo hematopoietic stem cell culture.

Authors:  Dandan Li; Grace Chiu; Brea Lipe; Richard A Hopkins; Jacquelyn Lillis; John M Ashton; Soumen Paul; Omar S Aljitawi
Journal:  Blood Adv       Date:  2019-04-09

2.  Three-Dimension Co-culture of Hematopoietic Stem Cells and Differentiated Osteoblasts on Gallic Acid Grafted-Chitosan Scaffold as a Model of Hematopoietic Stem Cells Niche.

Authors:  Jin Wang; Minghao Xiong; Qihao Sun; Wen-Song Tan; Haibo Cai
Journal:  Stem Cell Rev Rep       Date:  2022-01-05       Impact factor: 5.739

3.  Wharton's jelly mesenchymal stem cell-based or umbilical vein endothelial cell-based serum-free coculture with cytokines supports the ex vivo expansion/maintenance of cord blood hematopoietic stem/progenitor cells.

Authors:  Qiuyang Li; Dewan Zhao; Qiang Chen; Maowen Luo; Jingcao Huang; Cao Yang; Fangfang Wang; Wenxian Li; Ting Liu
Journal:  Stem Cell Res Ther       Date:  2019-12-05       Impact factor: 6.832

Review 4.  Wharton's jelly-derived stromal cells and their cell therapy applications in allogeneic haematopoietic stem cell transplantation.

Authors:  Cécile Pochon; Anne-Béatrice Notarantonio; Caroline Laroye; Loic Reppel; Danièle Bensoussan; Allan Bertrand; Marie-Thérèse Rubio; Maud D'Aveni
Journal:  J Cell Mol Med       Date:  2022-01-28       Impact factor: 5.310

5.  Simultaneous harvesting of endothelial progenitor cells and mesenchymal stem cells from the human umbilical cord.

Authors:  Hao Zhang; Yanling Tao; Saisai Ren; Haihui Liu; Hui Zhou; Jiangwei Hu; Yongyong Tang; Bin Zhang; Hu Chen
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

Review 6.  The Effect of Mesenchymal Stem Cell-Derived Extracellular Vesicles on Hematopoietic Stem Cells Fate.

Authors:  Hamze Timari; Karim Shamsasenjan; Aliakbar Movassaghpour; Parvin Akbarzadehlaleh; Davod Pashoutan Sarvar; Sara Aqmasheh
Journal:  Adv Pharm Bull       Date:  2017-12-31

7.  Hypoxia with Wharton's jelly mesenchymal stem cell coculture maintains stemness of umbilical cord blood-derived CD34+ cells.

Authors:  Dewan Zhao; Lingjia Liu; Qiang Chen; Fangfang Wang; Qiuyang Li; Qiang Zeng; Jingcao Huang; Maowen Luo; Wenxian Li; Yuhuan Zheng; Ting Liu
Journal:  Stem Cell Res Ther       Date:  2018-06-13       Impact factor: 6.832

Review 8.  Chicken Mesenchymal Stem Cells and Their Applications: A Mini Review.

Authors:  Andrea Svoradova; Vladimir Zmrhal; Eva Venusova; Petr Slama
Journal:  Animals (Basel)       Date:  2021-06-24       Impact factor: 2.752

9.  Mesenchymal stem cells from different sources show distinct therapeutic effects in hyperoxia-induced bronchopulmonary dysplasia in rats.

Authors:  Yingjun Xie; Fei Chen; Lei Jia; Rui Chen; Victor Wei Zhang; Xinqi Zhong; Ding Wang
Journal:  J Cell Mol Med       Date:  2021-07-29       Impact factor: 5.310

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.